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OBJECTIVE: With the increasing prevalence of steatosis, the number of steatotic liver grafts from deceased
donors is also increasing. Thus, determining the prevalence and the population risk factors of steatosis may
assist in risk stratification. The aim of this study was to evaluate the prevalence and predictors of steatosis and
steatohepatitis among livers from adults who died due to non-burn trauma.
METHODS: Specimens were collected from 224 adults undergoing autopsy at a regional autopsy referral center
from September 2011 to April 2013. Histopathological examination was performed on six samples obtained
from different lobes of each liver. The outcomes of interest were the presence of steatosis, steatohepatitis, NASH
inflammation and NASH fibrosis. The main predictors were body mass index, abdominal circumference, liver
weight and volume, presence of cholelithiasis, and siderosis. Our modeling strategy made use of a series of
generalized linear models with a binomial family.
RESULTS: Our sample had a mean age of 40 years; steatosis was diagnosed in 48.2% of cases, and steatohepatitis
was diagnosed in 2.7%. The presence of a high proportion of fatty changes was more prevalent among males
and older individuals, with the most affected age group being 41-60 years. When evaluating the crude odds
ratio for steatosis, the factors significantly associated with an increased risk of steatosis were greater abdominal
circumference, BMI, and liver weight and the presence of siderosis.
CONCLUSION: Our study reinforces the role of older age, obesity and hepatomegaly as predictors of fatty liver
disease. These variables should be considered in the assessment of fatty changes in the livers of potential liver
donors.
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’ INTRODUCTION
Steatosis or the abnormal retention of triglycerides and
other fat vacuoles in hepatocytes is a common cause of
hepatic disease (1). It has a high prevalence among heavy
alcohol drinkers (2), as well as those with diagnoses of
hepatitis C infection (1), diabetes, and dyslipidemia and
obese individuals (3). Non-alcoholic fatty liver disease
(NAFLD) can occur concomitantly with hepatocyte inflam-
mation, in which case it is referred to as non-alcoholic
steatohepatitis (NASH) (1,3). With the increasing preva-
lence of steatosis, the number of steatotic liver grafts from
deceased donors is also increasing (4). Because the transplan-
tation of steatotic liver grafts is associated with complica-
tions including reperfusion injuries and graft failure (5), it is
important to understand steatosis risk factors in an otherwise
normal population. Routine liver biopsy as a pretransplanta-
tion work-up is challenging because only over 20% of all liver
transplants in the United Network for Organ Sharing (UNOS)
have a recorded liver donor biopsy (5). The lack of liver donor
biopsy is further worsened in settings in which histopatho-
logical services are not provided on a 24-hour basis in the
transplantation centers (6). Thus, determining the actual
prevalence and the risk factors for steatosis in the normal
population may assist in stratifying the risk of steatosis in
potential liver donors soon after harvesting the liver.
The population prevalence of steatosis depends on the
diagnostic test being used. Currently, modalities for diagnos-
ing steatosis range from imaging techniques to biopsy, and
these techniques have different accuracy levels in different
contexts. Imaging techniques are generally used to screen
for patients who may need biopsy, and these techniques
also have a set of limitations. Ultrasound, for example, is an
operator-dependent procedure with variable results (7) andDOI: 10.6061/clinics/2019/e1070
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is limited in terms of its accuracy with regard to detecting
mild steatosis (8) as well as examining morbidly obese
patients (9,10). Similarly, computerized tomography (CT)
scanning can detect mild steatosis relatively less accurately,
unless unsafe levels of radiation are used (11). Furthermore,
magnetic resonance imaging (MRI) and magnetic resonance
spectroscopy (MRS) have superior detection rates com-
pared to those of CT and ultrasound but are also limited
in their ability to produce information that can be used
to stage NAFLD (12). Moreover, these tools are expensive
and not necessarily available during the peri-harvesting
procedure.
On the other hand, liver biopsy is considered the gold
standard for diagnosis. This standard was established
despite its shortcomings, including false negatives, in cases
in which the distribution of non-alcoholic steatohepatitis
lesions in the parenchyma is irregular (13,14) as well as high
interobserver variability in evaluating lobular inflammation
and ballooning (15). In addition, due to the invasiveness of
this procedure, clinicians tend to not consider it a required
step in the management of fatty liver disease, with diagnostic
biopsy being performed only in select patients. Therefore,
liver biopsy performed on live patients is usually not a
practical option to determine the true prevalence among the
general population.
Given the challenges of donor liver biopsy prior to
transplantation and the limitations of contemporary diag-
nostic modalities in describing steatosis in the general popu-
lation, evaluating cadaveric livers might provide a way to
determine the risk of fatty liver disease, ultimately assisting
clinicians in evaluating organ quality. To the best of our
knowledge, however, no previous study has evaluated the
predictors of steatosis and steatohepatitis in cadaveric livers.
To bridge this gap in the literature, this study aimed to
evaluate steatosis and steatohepatitis in the livers of adults
after their deaths due to non-burn trauma.
’ METHODS
Study design
This was a prospective cohort study evaluating steatosis
and steatohepatitis in adults who died due to non-burn
trauma. The study is described in accordance with the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) guidelines (16). A total of 224 cases
were included in this analysis.
Ethics
Our study was approved by the Institutional Review
Boards of the Schools of Medicine at the University of São
Paulo (CAPPesq, HCFMUSP) and the Federal University of
Tocantins (UFT) in accordance with the general direction of
the Legal Medical Institute (IML) of Palmas-TO. Informed
consent was obtained from all family members or legal
guardians of the investigated deceased and was signed prior
to any study protocol being implemented.
Setting
Specimens were collected from 224 adult cadavers under-
going autopsy at the Legal Medical Institute (IML) of Palmas,
Brazil, from September 2011 to April 2013. The Legal Medical
Institute (IML) is located in Northern Brazil, serving a popu-
lation of approximately 320,000 people living in 17 surround-
ing towns. All autopsies were part of a forensic investigation
performed on those with unnatural deaths, with mechanisms
including accidents and other non-burn trauma.
Participants
We only included individuals who were 18 years or older
and died due to a non-burn trauma. We excluded those who
(1) had died more than 24 hours prior to autopsy to provide
adequate time for analysis, without the risk of significant
histological changes, (2) had spent more than 24 hours in the
hospital to avoid histological changes due to therapeutic
action and early hepatic dysfunction during hospitalization
(17), (3) had experienced major direct trauma to the liver, and
(4) had an undetermined cause of death; we also excluded
those whose families did not authorize the procedure. Cases
presenting technical challenges were also excluded, includ-
ing problems with slide staining, failure to acquire sample
tissue, logistical problems and defects in the generation of
paraffin blocks (Figure 1).
Sample examination
After obtaining a history of alcohol consumption and
any previous liver disease from a first-degree relative, the
anthropometric parameters of each corpse were measured,
and samples were obtained for pathological examination.
The histopathological examination was conducted by a
pathologist in the Research Laboratory on Liver Pathology
at the University of São Paulo. From a sagittally sectioned
liver, a total of six samples, each measuring 2 centimeters by
1.5 centimeters, were obtained from the subcapsular and
intraparenchymal areas of the right posterior, central and left
lateral lobes of the liver. A total of 1,344 biopsies were
therefore collected from the 224 deceased individuals. All
samples were processed, sectioned, and stained with hema-
toxylin-eosin, Perls, trichrome Masson and Picrosirius; a total
of 5,376 slides were examined for the purposes of this study.
Outcomes
The outcomes of interest were the detection of steatosis,
steatohepatitis, NASH inflammation and NASH fibrosis on
the histopathological examination. Steatosis was determined
by estimating the proportion of hepatocytes containing fat
droplets (macrovesicular or microvesicular), which was con-
verted to grades as follows: Grade 0 (less than 5%), Grade 1
(5-33%), Grade 2 (33-66%) and Grade 3 (above 66%). The
topography of steatosis cells was categorized as zone 1
(periportal area), zone 3 (centrilobular area) and zone 2
(intermediate between zones 1 and 3). Steatohepatitis was
determined by the NAFLD activity score (NAS), as proposed
by the Non-alcoholic Steatohepatitis Clinical Research Net-
work (NASH-CRN) Pathology Committee, which is based
on the sum of each histological component evaluated as
follows: steatosis (0-3), ballooning (0-2), and lobular inflam-
mation (0-3). Cases with NAS scores of 0-2 were considered
to not have steatohepatitis, those with scores of 3-4 were
considered to have borderline steatohepatitis, and those
with scores greater or equal to 5 were considered to have
a definitive steatohepatitis diagnosis (18). The histological
lesions considered while determining the NASH grade
included steatosis, ballooning and inflammation. These were
graded semiquantitatively on a scale where 0 = absent, 1 =
mild, 2 = moderate, and 3 = severe (18). NASH inflammation
was assessed through an evaluation of inflammatory foci per
20X field characterized by a mixed inflammatory infiltrate
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composed of neutrophils and mononuclear cells, evaluated
as Grade 0 (no foci), Grade 1 (less than 2 foci), Grade 2 (2-4
foci) and Grade 3 (greater than 4 foci) (18). NASH fibrosis
pathological staging was performed as proposed by Kleiner:
1 = perisinusoidal or periportal; 2 = perisinusoidal and
periportal; 3 = bridging fibrosis and 4 = cirrhosis (18).
Predictors
Our main predictors were body mass index (weight in
kilograms over the square of height in meters); abdominal
circumference in centimeters (cm) at the umbilical level; liver
weight in grams; liver volume calculated as a product of the
height (cm), width (cm) and length (cm) of the liver; the
presence of cholelithiasis; hepatic iron overload (siderosis)
assessed based on the cellular distribution of iron deposits
within the Kupffer cells, hepatocytes, and macrophages;
and the presence of siderosis, histologically graded as 0 =
granules absent or barely discernible, 1 = granules barely
discernible but present, 2 = discrete granules resolved at x
100, 3 = 3 discrete granules resolved at x 50 or 4 = granules
Figure 1 - Flowchart detailing the inclusion and exclusion of cases.
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visible to the naked eye (19). Any siderosis was considered as
the presence of siderosis among Kupffer cells, hepatocytes or
macrophages.
Potential confounding variables
Our potential confounders were selected based on evi-
dence from previous studies combined with clinical judg-
ment (20). Specifically, we selected age and sex as potential
confounding variables.
Data analysis
Our exploratory analysis started by evaluating the
distributions, frequencies and percentages for each of the
numeric and categorical variables. Categorical variables were
evaluated for near-zero variation (21). Extensive graphical
displays were used for both univariate analysis and bivariate
associations, accompanied by broader tests such as the Maxi-
mal Information Coefficient (22) and Nonnegative Matrix
Factorization (23) algorithms for numeric variables.
Our modeling strategy made use of a series of generalized
linear models with a binomial family to assess the associa-
tions of the investigated variables with steatosis or steatohe-
patitis as the outcome variables. The predictors included body
mass index (body weight in kilograms over height squared in
meters), abdominal circumference (centimeters), liver weight
(grams), liver volume (cubic centimeter), the presence of
cholelithiasis, and hepatic iron overload (siderosis).
We then performed an analysis using unsupervised tree
models for hierarchical clustering (24) to identify the most
common associations and hierarchical patterns among the
following variables: abdominal circumference, liver weight,
liver volume, the presence of cholelithiasis, and hepatic iron
overload (siderosis).
All analyses were performed using the R language and the
following packages: ggplot2 and rmarkdown.
’ RESULTS
Participant characteristics
A total of 697 cases were assessed initially, with 225
excluded either because the time of death was more than
24 hours prior to autopsy, the hospitalization duration was
over 24 hours, the liver was severely damaged by trauma,
the cause of death was undetermined, the individual was
younger than 18 years of age or the family did not provide
consent. A further 248 were lost in the histological process
due to problems with slide staining and the failure to acquire
samples or logistics. Thus, 224 cases were included in our
final analysis. Our sample had a mean age of 39.7 (±16.57)
years, with a higher proportion of fatty liver changes
observed in males, and the most commonly affected age
group was the group from 41 to 60 years old. Steatosis was
diagnosed in 48.2% of all cases, with steatohepatitis being
detected in 2.7% of the cases (Table 1).
Outcomes
Among those with hepatocyte fatty changes, a majority of
cases (80.6%) were Grade 1 steatosis, with 50% of steatohe-
patitis cases classified as Grade 2. Ballooning was detected in
15/224 (6.7%) cases, 60% of which were Grade 1. Less than
half (41.5%) of the cases were classified as Grade 1 NASH
inflammation. Four cases were NASH fibrosis, and three
were classified as steatosis. Steatohepatitis was identified in
two of these steatosis cases. Hepatic iron overload was
detected in 8% of all cases and 13% of cases with steatosis,
and it was present in hepatocytes, Kupffer cells or macro-
phages. However, iron overload was only present in one case
of steatohepatitis. Although the presence of Mallory Denk
bodies is not regarded as a characteristic feature of steato-
hepatitis, it was present in 5 out of 6 cases of steatohepatitis
(Table 2).
The odds of steatosis (unadjusted and adjusted) were
higher in individuals with increased abdominal circumfer-
ence, BMI, and liver weight. In addition, the presence of any
siderosis was also associated with steatosis. These associa-
tions were still significant after adjusting for age and sex
(Table 3).
A further tree regression model demonstrated that an
abdominal circumference greater than 90 centimeters was the
most important risk factor for steatosis, and a BMI greater
than 24 was a risk factor in those with abdominal circum-
ferences greater than 77 centimeters (Figure 2).
’ DISCUSSION
To the best of our knowledge, this is the first study
evaluating steatosis and steatohepatitis in adults who died
due to non-burn trauma. We found a 48.2% prevalence of
steatosis, with a significant upward trend in higher age
groups, except in individuals over 60 years. An increased
risk of steatosis was associated with obesity and hepatome-
galy, as evaluated through the measures of BMI, abdominal
circumference, liver weight and volume, and siderosis. We
also found a total of six cases of steatohepatitis and four cases
of NASH fibrosis, two of which were in individuals with
steatohepatitis.
Our study found that fatty liver disease is common
among individuals who have died due to non-burn trauma.
Table 1 - Sample characteristics with anthropometric data stratified by steatosis and steatohepatitis.
Variable Total (224) Steatosis (108) Steatohepatitis (6)
Age 39.7 (±16.57) 41.75 (±15.02) 47.17 (±8.95)
Age Categories (years)
- less than or equal to 20 24 (10.7%) 7 (6.5%) 0 (0%)
- 21 to 40 107 (47.8%) 45 (41.7%) 1 (16.7%)
- 41 to 60 69 (30.8%) 46 (42.6%) 5 (83.3%)
- greater than 60 24 (10.7%) 10 (9.3%) 0 (0%)
Female 41 (18.3%) 19 (17.6%) 0 (0%)
BMI 24.25 (±4.69) 26.04 (±4.99) 31.52 (±5)
Liver Volume (cm3) 3403.67 (±1771.02) 3624.85 (± 1889.62) 6148 (±2840.39)
Liver Weight (g) 1586.41 (±412.54) 1674.59 (±469.02) 2228.17 (±791.03)
Abdominal Circumference (cm) 84.65 (±18.05) 91.59 (±19.56) 113.33 (±21.56)
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Importantly, the overall rate of fatty liver disease in our
sample was higher than in most previous population-based
studies. A systematic review reported the prevalence of
NAFLD in the general population to be as high as 35% (25-
28). However, most previous prevalence reports were based
on noninvasive diagnostic protocols, such as radiological
modalities or serum biomarkers, which tend to underesti-
mate the prevalence of this condition. It is also noteworthy
that autopsy series describing the prevalence of NAFLD
have presented wide variability in their results, ranging from
3 to 50% (28-30). There are a number of possible explanations
for this variation, including heterogeneity in sample char-
acteristics regarding age, ethnicity, health status, history of
alcohol consumption, and dietary habits (31,32). Moreover,
several methodological factors can affect the histopathologi-
cal evaluation, including the interval between the time of
death and the examination, as well as the quality of biopsy
techniques. Finally, histological findings and diagnostic
categories are subject to interobserver disagreement (33).
These findings emphasize the importance of standardizing
protocols in future studies evaluating fatty liver disease
among potential organ donors considered to be in good
health, so that results can be deemed comparable.
The pathogenesis and natural history of NAFLD have
been the subjects of controversy, as multiple theories have
been proposed. Several factors may be involved, including
insulin resistance, oxidative stress, inflammation, and dys-
functional hepatocyte apoptosis (34-36). The role of oxidative
stress in the development of NAFLD may explain the
positive association between siderosis and steatosis in our
sample, as hepatic iron overload increases oxidative damage
to tissues (37-40). It is possible that biomarkers of iron
metabolism and imaging techniques evaluating hepatic iron
overload may have predictive value in fatty liver disease.
Table 2 - Histopathological data from study sample, stratified by steatosis and steatohepatitis.
Variable [Missing] Total (224) Steatosis (108) Steatohepatitis (6)
Steatosis Grade [116]
-1 87 (80.6%) 87 (80.4%) 2 (33.3%)
-2 11 (10.2%) 11 (10.3%) 3 (50%)
-3 10 (9.3%) 10 (9.3%) 1 (16.7%)
Ballooning Grade [209]
-1 9 (60%) 9 (60%) 2 (33.3%)
-2 3 (20%) 3 (20%) 2 (33.3%)
-3 3 (20%) 3 (20%) 2 (33.3%)
NASH Inflammation Grade [0]
0 129 (57.6%) 14 (13%) 0 (0%)
-1 93 (41.5%) 92 (85.2%) 4 (66.7%)
-2 2 (0.9%) 2 (1.9%) 2 (33.3%)
NASH Inflammation [0] 95 (42.4%) 94 (87%) 6 (100%)
Mallory Denk Bodies [0] 8 (3.6%) 8 (7.5%) 5 (83.3%)
NASH Fibrosis Grade [0]
0 220 (98.2%) 105 (97.2%) 4 (66.7%)
-1 2 (0.9%) 1 (0.9%) 0 (0%)
-2 2 (0.9%) 2 (1.9%) 2 (33.3%)
NASH Fibrosis [0] 4 (1.8%) 3 (2.8%) 2 (33.3%)
Siderosis Kupffer Cells Grade [0]
0 214 (95.5%) 100 (92.6%) 5 (83.3%)
-1 9 (4%) 7 (6.5%) 1 (16.7%)
-2 1 (0.4%) 1 (0.9%) 0 (0%)
Siderosis Kupffer cells [0] 10 (4.5%) 8 (7.4%) 1 (16.7%)
Siderosis Hepatocytes Grade [0]
0 220 (98.2%) 106 (98.1%) 6 (100%)
-1 4 (1.8%) 2 (1.9%) 0 (0%)
Siderosis Hepatocytes [0] 4 (1.8%) 2 (1.9%) 0 (0%)
Siderosis Macrophage [0]
0 219 (97.8%) 103 (95.4%) 6 (100%)
-1 3 (1.3%) 3 (2.8%) 0 (0%)
-3 2 (0.9%) 2 (1.9%) 0 (0%)
Siderosis Macrophages 5 (2.2%) 5 (4.6%) 0 (0%)
Any Siderosis [1] 18 (8%) 14 (13%) 1 (16.7%)
Cholelithiasis [0] 3 (1.3%) 2 (1.9%) 0 (0%)
Table 3 - Crude odds ratio (unadjusted and adjusted) and 95% Confidence Intervals of Steatosis diagnosis.
Variables Steatosis Unadjusted OR (CI 95%) Steatosis Adjusted OR (CI 95%)
Abdominal Circumference 3.72 (2.13, 6.48) 3.51 (1.95, 6.32)
BMI 3.25 (1.88, 5.61) 3.25 (1.82, 5.82)
Liver Volume 1.49 (0.88, 2.52) 1.47 (0.85, 2.56)
Liver Weight 1.92 (1.13, 3.27) 1.86 (1.05, 3.29)
Siderosis Hepatocytes 1.08 (0.15, 7.77) 1.09 (0.14, 8.37)
Siderosis Kupffer cells 4.56 (0.95, 21.98) 3.75 (0.74, 19.08)
Any Siderosis 4.17 (1.33, 13.1) 4.12 (1.27, 13.35)
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In our study, only a small percentage of subjects had
steatohepatitis and/or NASH fibrosis. Although theoretical
models have proposed that NAFLD comprises a continuum
of hepatocyte lesions from steatosis to NASH and fibrosis
(35,41-43), these models have been questioned in the most
recent literature. For example, several studies have argued
that steatosis and NASH are distinct conditions within the
NAFLD concept, as both exhibit different pathophysiologi-
cal, histological, and clinical features (44,45). Further studies
should provide a more comprehensive model explaining
the underlying fatty liver disease mechanisms, including
the relationship between steatosis and NASH, as well as
variables associated with prognosis in both conditions.
The higher risk of steatosis and NASH among obese
individuals in our sample is consistent with the literature
emphasizing the importance of obesity as a risk factor for
fatty liver disease. Accordingly, NAFLD is considered the
hepatic component of metabolic syndrome, a cluster of
conditions including central fat accumulation, insulin resis-
tance, diabetes, dyslipidemia, and hypertension (46-51). The
deposition of fat in the liver may lead to hepatomegaly,
which is consistent with the higher risk of NAFLD among
subjects with increased liver weight and volume (52,53).
Previous studies estimated the rates of NAFLD among obese
individuals to be as high as 74% (54). The association
between obesity and NAFLD is likely a consequence of the
large sources of fatty acids in obese individuals, which
originate from adipose tissue and are combined with the less
effective insulin-mediated suppression of lipolysis (55,56).
The exact extent of the contribution of obesity as a cause
of NAFLD is difficult to determine, as obese individuals also
present high rates of other risk factors for NAFLD, such as
dyslipidemia and diabetes.
Another finding in our sample was the significantly higher
prevalence of fatty liver disease and especially of steatohe-
patitis among individuals who were older, possibly as a
result of higher rates of metabolic disorders in this age group
(57,58). These individuals will also typically have a longer
disease duration. Considering theories that describe NAFLD
as a continuum, higher rates of NASH among older subjects
might indicate disease progression (36,59,60). Conversely, in
our sample, this trend did not extend to individuals over
60 years. The relatively small number of subjects in this age
range may have contributed to our findings because the
progressively higher risk of NAFLD among older indivi-
duals has been consistently reported in a number of previous
studies (61,62).
Despite filling a gap in the literature, our study does have
limitations. First, a significant number of samples were lost
due to technical issues. In spite of this problem, data from a
large number of individuals were still obtained. Second,
because we used a convenience sample, the external validity
of our findings can be questioned. Despite this limitation,
our sample was obtained from a referral center in charge of
conducting autopsies for the entire region, which might have
minimized our selection bias. Third, we did not account for
Figure 2 - Tree regression model with risk factors for steatosis.
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trauma-related oxidative stress, which might have artificially
inflated the rates of steatosis when compared with other
causes of death (25,26). Our analysis, however, included data
from a large sample of individuals, providing robust results
regarding the factors predicting NAFLD among potential
liver donors in similar populations. Although the impact of
oxidative stress is still controversial, a control group of
individuals who died from nontraumatic causes could be
used to adjust the rate of steatosis in future studies. Fourth,
we did not consider the roles of other comorbidities, such as
alcohol abuse, hepatitis, and diabetes, as predictors of steatosis
or steatohepatitis. Nevertheless, these conditions have already
been recognized as risk factors for steatosis in a number of
previous studies (1-3,25-27). Finally, the histopathological
findings in our biopsy samples were not validated through
agreement across different pathology specialists.
In conclusion, our study reinforces the roles of older age,
obesity and hepatomegaly as predictors of fatty liver disease.
These variables should be considered in the assessment of
liver fatty changes among potential liver donors. Further
studies should focus on the development of reliable algori-
thms for diagnosing fatty liver disease, which may include
clinical aspects, laboratory findings, and imaging tests.
Finally, larger, longitudinal studies should expand the
knowledge of the epidemiological and pathophysiological
features of fatty liver disease, providing support for future
clinical guidelines.
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